Key facts
- It has raised $138.1M.
- Notable investors include OrbiMed, Novo Holdings, Johnson & Johnson JJDC, M Ventures, EQT Life Sciences — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Asceneuron
- ·The full record, as it builds
Funding rounds
No funding rounds for Asceneuron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asceneuron
Developer of therapeutic compounds designed to treat neurodegenerative disorders. The company focuses on developing treatments for a wide range of neurodegenerative diseases, including orphan tauopathies, Alzheimer's, and Parkinson's disease, enabling medical professionals to access suitable therapies to improve the lives of patients affected by neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2012
- Employees
- 18
- Website
- asceneuron.com/
- Ownership
- Privately Held (backing)
Asceneuron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asceneuron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asceneuron in its N-PORT filings yet. We sweep new filings monthly.